Bristol-Myers Squibb Company (BMY) Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibikase Therapeutics  
2/3/2012 6:40:37 AM

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR) for its tender offer for Inhibitex, Inc. (NASDAQ: INHX) has expired.